$RNGE
RANGE IMPACT, INC. Stock $rnge

$rnge Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-K Financial Statement

#000114420414040441 Filed on June 30, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2014
Revenue	$41.44K	$0.00	$0.00
YoY Change
Cost Of Revenue	$11.88K		$120.0K
YoY Change
Gross Profit	$29.57K		$120.0K
YoY Change
Gross Profit Margin	71.34%
Selling, General & Admin	$590.0K	$790.0K	$2.800M
YoY Change	-23.38%		-7.28%
% of Gross Profit	1995.54%		2333.33%
Research & Development	$246.0K	$30.00K	$575.1K
YoY Change	99.6%		-21.91%
% of Gross Profit	831.97%		479.24%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$833.0K	$820.0K	$575.1K
YoY Change	-6.47%		-21.91%
Operating Profit	-$803.4K		-$3.598M
YoY Change	-9.79%		41.14%
Interest Expense	$657.00	-$610.0K	$404.3K
YoY Change	-99.66%		16.55%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$660.0K	-$1.430M	-$4.050M
YoY Change	-26.67%		-2.41%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$655.8K	-$1.430M	-$4.153M
YoY Change	-27.08%		51.42%
Net Earnings / Revenue	-1582.48%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.10	-$0.22	-$0.57
COMMON SHARES
Basic Shares Outstanding	67.11M shares	66.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$830.0K	$1.400M	$390.0K
YoY Change	-29.06%		-72.14%
Cash & Equivalents	$830.1K	$1.403M
Short-Term Investments
Other Short-Term Assets	$10.00K	$20.00K	$0.00
YoY Change	-90.91%		-100.0%
Inventory	$15.87K	$0.00	$10.00K
Prepaid Expenses	$9.464K	$10.64K
Receivables	$27.93K	$0.00	$60.00K
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$880.0K	$1.424M	$460.0K
YoY Change	-31.34%	169.24%	-67.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00
YoY Change
Total Long-Term Assets	$3.384K	$0.00	$0.00
YoY Change		-100.0%
TOTAL ASSETS
Total Short-Term Assets	$880.0K	$1.424M	$460.0K
Total Long-Term Assets	$3.384K	$0.00	$0.00
Total Assets	$883.4K	$1.424M	$460.0K
YoY Change	-31.08%	164.05%	-67.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$160.0K	$80.00K	$130.0K
YoY Change	-11.11%		62.5%
Accrued Expenses		$0.00
YoY Change		-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.470M	$1.535M	$1.540M
YoY Change	-11.4%	191.14%	0.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.470M	$1.535M	$1.540M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.475M	$1.535M	$1.540M
YoY Change	-33.91%	38.58%	0.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.983M	-$8.327M
YoY Change	-277.06%	99.49%
Common Stock	$67.21K	$66.83K
YoY Change	12.42%	20.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$591.4K	-$110.4K	-$1.080M
YoY Change
Total Liabilities & Shareholders Equity	$883.4K	$1.424M	$460.0K
YoY Change	-31.08%	164.05%	-67.61%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2014
OPERATING ACTIVITIES
Net Income	-$655.8K	-$1.430M	-$4.153M
YoY Change	-27.08%		51.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$590.0K	-$530.0K	-$2.500M
YoY Change	64.13%		17.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$10.00K	$0.00	$10.00K
YoY Change
Cash From Investing Activities	$10.00K	$0.00	$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.133M
YoY Change			166.65%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	110.0K	1.480M
YoY Change	-99.12%		-52.87%
NET CHANGE
Cash From Operating Activities	-590.0K	-530.0K	-2.500M
Cash From Investing Activities	10.00K	0.000	10.00K
Cash From Financing Activities	10.00K	110.0K	1.480M
Net Change In Cash	-570.0K	-420.0K	-1.010M
YoY Change	-173.67%		-200.0%
FREE CASH FLOW
Cash From Operating Activities	-$590.0K	-$530.0K	-$2.500M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	10413	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2025000	shares
CY2014	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	156400	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	736420	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	575092	USD
CY2013Q1	us-gaap	Cash Cash	392483	USD
CY2014Q1	us-gaap	Cash Cash	1403403	USD
CY2013Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11573	USD
CY2014Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10637	USD
CY2013Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	125000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	529056	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	1424453	USD
CY2013Q1	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	10417	USD
CY2014Q1	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2013Q1	us-gaap	Assets Assets	539473	USD
CY2014Q1	us-gaap	Assets Assets	1424453	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	112263	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	79915	USD
CY2013Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	6930	USD
CY2014Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	16100	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9375	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0	USD
CY2013Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	398603	USD
CY2014Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1438814	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	527171	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1534829	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3143753	USD
CY2014	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2013Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	374592	USD
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2013Q1	us-gaap	Liabilities Liabilities	1107579	USD
CY2014Q1	us-gaap	Liabilities Liabilities	1534829	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	55659	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	66833	USD
CY2013Q1	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	157500	USD
CY2014Q1	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	149714	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3707772	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8299366	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4174037	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8326861	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-568106	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-110376	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	539473	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1424453	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Use of Estimates and Assumptions</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of shares issued for services, fair value of warrants issued in conjunction with convertible debentures, and assumptions used in the valuation of conversion features and derivative liabilities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Derivative Financial Instruments</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses the probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2014 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	stvf	Warrants Granted Period In Weighted Exercise Price WarrantsGrantedPeriodInWeightedExercisePrice	0.34
	stvf	Minimum Warrants Exercise Price MinimumWarrantsExercisePrice	0.20
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	170000	USD
CY2014	stvf	Payment Of Costs Related To Purchase Agreement PaymentOfCostsRelatedToPurchaseAgreement	578458	USD
CY2013Q1	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.50
CY2013Q1	us-gaap	Share Price SharePrice	0.45
CY2014Q1	us-gaap	Share Price SharePrice	0.41
CY2013	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0025	pure
CY2013	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.2368	pure
CY2014Q1	stvf	Stock Options To Purchase StockOptionsToPurchase	5150000	shares
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	955000	USD
CY2014Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	USD
CY2013Q1	us-gaap	Long Term Debt LongTermDebt	580408	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	525000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	525000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55659102	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66832523	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55659102	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66832523	shares
CY2012Q1	stvf	Common Subscription Shares CommonSubscriptionShares	625000	shares
CY2012Q1	stvf	Convertible Debenture Total ConvertibleDebentureTotal	625000	USD
CY2012Q1	stvf	Debenture Subscription Tranche DebentureSubscriptionTranche	693774	USD
CY2014Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.45
CY2012Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000	USD
CY2014	stvf	Loan Placement Fees LoanPlacementFees	55000	USD
CY2014Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	523458	USD
CY2012Q4	stvf	Warrants To Purchase Of Common Stock WarrantsToPurchaseOfCommonStock	1000000	shares
CY2014Q1	stvf	Free Standing Derivative Value FreeStandingDerivativeValue	500000	USD
CY2012Q4	stvf	Free Standing Derivative Value FreeStandingDerivativeValue	500000	USD
CY2012Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	445000	USD
CY2014	stvf	Conversion Shares Issuable To Purchaser Percentage ConversionSharesIssuableToPurchaserPercentage	1	pure
CY2013Q1	stvf	Warrants Exercise Price WarrantsExercisePrice	0.50
CY2014	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	733334	shares
CY2013	stvf	Debenture Outstanding Amount DebentureOutstandingAmount	330000	USD
CY2012Q4	stvf	Warrants Granted In Period WarrantsGrantedInPeriod	1000000	shares
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.9215	pure
CY2013	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P4Y6M
CY2013	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	124855	USD
CY2014	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	193915	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Noncash Considerations StockIssuedDuringPeriodValueIssuedForNoncashConsiderations	1249025	USD
	us-gaap	Stock Issued During Period Value Issued For Noncash Considerations StockIssuedDuringPeriodValueIssuedForNoncashConsiderations	1249025	USD
CY2014	stvf	Number Of Common Stock To Be Issued Upon Exercise Of Warrants NumberOfCommonStockToBeIssuedUponExerciseOfWarrants	3676472	Warrant
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2100000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4225000	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1750000	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1250000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2275000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5150000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4291670	shares
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.10
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.29
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.16
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.29
CY2014	stvf	Weighted Average Remaining Vesting Period WeightedAverageRemainingVestingPeriod	P2Y
CY2012Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2013	stvf	Warrants Granted In Period WarrantsGrantedInPeriod	1080000	shares
CY2014	stvf	Warrants Granted In Period WarrantsGrantedInPeriod	11323601	shares
CY2013	stvf	Warrants Exercised In Period WarrantsExercisedInPeriod	0	shares
CY2014	stvf	Warrants Exercised In Period WarrantsExercisedInPeriod	4676472	shares
CY2013	stvf	Warrants Cancelled In Period WarrantsCancelledInPeriod	0	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1080000	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7727129	shares
CY2014Q1	stvf	Warrants Exercisable WarrantsExercisable	7727129	shares
CY2012Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0
CY2013	stvf	Warrants Granted Period In Weighted Exercise Price WarrantsGrantedPeriodInWeightedExercisePrice	0.50
CY2014	stvf	Warrants Granted Period In Weighted Exercise Price WarrantsGrantedPeriodInWeightedExercisePrice	0.50
CY2014	stvf	Warrants Exercised Period In Weighted Exercise Price WarrantsExercisedPeriodInWeightedExercisePrice	0.41
CY2013	stvf	Warrants Cancelled In Period Weighted Exercise Price WarrantsCancelledInPeriodWeightedExercisePrice	0
CY2013Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.50
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.41
CY2012Q4	stvf	Warrants Granted Period In Weighted Exercise Price WarrantsGrantedPeriodInWeightedExercisePrice	0.70
CY2013Q4	stvf	Warrants Granted Period In Weighted Exercise Price WarrantsGrantedPeriodInWeightedExercisePrice	0.42
CY2013Q4	stvf	Warrants Exercised WarrantsExercised	314000	shares
CY2013Q4	stvf	Warrants Exercised WarrantsExercised	3362472	shares
CY2014Q1	stvf	Aggregate Intrinsic Value Of Warrants Outstanding AggregateIntrinsicValueOfWarrantsOutstanding	42365	USD
CY2013Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	157000	USD
CY2014Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8326859	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1663799	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2866095	USD
CY2013	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	148750	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-2548969	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-3597587	USD
CY2013	us-gaap	Interest Expense InterestExpense	346912	USD
CY2013	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-1000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2013	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-139723	USD
CY2014	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	1010920	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	532206	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	392483	USD
CY2014	us-gaap	Interest Expense InterestExpense	404317	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	107004	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	42	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-2742522	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-4152824	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53370064	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60128127	shares
CY2013Q1	stvf	Landlease Agreement Rent Ag LandleaseAgreementRentAg	148750	USD
CY2014Q1	stvf	Landlease Agreement Rent Ag LandleaseAgreementRentAg	156400	USD
CY2012Q3	stvf	Landlease Agreement Rent Ag LandleaseAgreementRentAg	1000	USD
CY2014	stvf	Initial Term Of Patents License Agreement InitialTermOfPatentsLicenseAgreement	P10Y
CY2014Q1	stvf	Cash Fees And Payable For Patents License Agreement CashFeesAndPayableForPatentsLicenseAgreement	50000	USD
CY2014	stvf	Percentage Of Royalties On Sale Price Of Products PercentageOfRoyaltiesOnSalePriceOfProducts	0.005	pure
CY2014Q1	stvf	Minimum Annual Royalty MinimumAnnualRoyalty	10000	USD
CY2014	stvf	Proceeds From Patent Prosecution Cost ProceedsFromPatentProsecutionCost	50000	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	-49231	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	409000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	325998	USD
CY2014	stvf	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1824505	USD
CY2013	stvf	Common Stock Issued Upon Conversion Of Convertible Notes Payable Value CommonStockIssuedUponConversionOfConvertibleNotesPayableValue	107004	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	31500	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	43786	USD
CY2013	stvf	Stock Issued During Period Value Accrued Interest StockIssuedDuringPeriodValueAccruedInterest	29500	USD
CY2014	stvf	Stock Issued During Period Value Accrued Interest StockIssuedDuringPeriodValueAccruedInterest	37501	USD
CY2014	stvf	Adjustments To Additional Paid In Capital Extinguishment Of Derivative Liabilities AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfDerivativeLiabilities	359734	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	833143	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1222031	USD
CY2013	us-gaap	Debt Issuance Costs DebtIssuanceCosts	78458	USD
CY2014	us-gaap	Debt Issuance Costs DebtIssuanceCosts	0	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	297884	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	374592	USD
CY2013	stvf	Cancellation Of Payable Of Option Exercise Price CancellationOfPayableOfOptionExercisePrice	196000	USD
CY2014	stvf	Cancellation Of Payable Of Option Exercise Price CancellationOfPayableOfOptionExercisePrice	0	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	7873	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-936	USD
CY2013	stvf	Payment For Advance To Related Party Lease PaymentForAdvanceToRelatedPartyLease	135417	USD
CY2014	stvf	Payment For Advance To Related Party Lease PaymentForAdvanceToRelatedPartyLease	-125004	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	36953	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	29686	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-3990	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	9170	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	32500	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	107652	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1646723	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2132833	USD
CY2013	stvf	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	870000	USD
CY2014	stvf	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	213000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	185998	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1508000	USD
CY2014	stvf	Issuance Of Common Stock Upon Conversion Of Notes Payable And Accrued Interest IssuanceOfCommonStockUponConversionOfNotesPayableAndAccruedInterest	994061	USD
CY2013	stvf	Fair Value Of Warrants Issued With Convertible Debentures FairValueOfWarrantsIssuedWithConvertibleDebentures	500000	USD
CY2014	stvf	Fair Value Of Warrants Issued With Convertible Debentures FairValueOfWarrantsIssuedWithConvertibleDebentures	0	USD
CY2013	stvf	Extinguishment Of Warrant Derivative Liabilities ExtinguishmentOfWarrantDerivativeLiabilities	0	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1403403	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Noncash Considerations StockIssuedDuringPeriodValueIssuedForNoncashConsiderations	0	USD
CY2013	stvf	Cancellation Of Accounts Payable Of Option Exercise Price CancellationOfAccountsPayableOfOptionExercisePrice	0	USD
CY2014	stvf	Cancellation Of Accounts Payable Of Option Exercise Price CancellationOfAccountsPayableOfOptionExercisePrice	140000	USD
CY2013	stvf	Issuance Of Common Stock Upon Conversion Of Notes Payable And Accrued Interest IssuanceOfCommonStockUponConversionOfNotesPayableAndAccruedInterest	556504	USD
CY2014	stvf	Extinguishment Of Warrant Derivative Liabilities ExtinguishmentOfWarrantDerivativeLiabilities	359734	USD
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>1.  BUSINESS AND BASIS OF OPERATIONS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left">Stevia First Corp. (the “Company”, “we”, “us” or “our”), was incorporated under the laws of the State of Nevada on June 29, 2007. During the period from July 1, 2007 to June 30, 2011, the Company commenced operations by issuing shares and acquiring a mineral property located in the Province of Saskatchewan, Canada. The Company was unable to keep the mineral claim in good standing due to lack of funding, and accordingly its interest in it has expired. On October 10, 2011, the Company completed a merger with its wholly-owned subsidiary, Stevia First Corp., whereby it changed its name from “Legend Mining Inc.” to “Stevia First Corp.” In connection with a related change in management, the addition of key personnel, and the lease of property for laboratory and office space in California, the Company is now pursuing its new business as an agricultural biotechnology company engaged primarily in developing novel methods and technologies for industrial production of stevia, using such methods and technologies to develop, obtain approval for and commercialize one or more stevia extract products, and exploring and commercializing additional research applications for such methods and technologies.  As of March 31, 2014, the Company had not produced any revenues.  The Company's fiscal year end is March 31.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), <i>Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.</i>  ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities.   ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk.  The presentation and disclosure requirements in Topic 915 are no longer required for interim and annual reporting periods beginning after December 15, 2014.  The revised consolidation standards will take effect in annual periods beginning after December 15, 2015, however, early adoption is permitted.  The Company adopted the provisions of ASU 2014-10 for this annual report on Form 10-K for the fiscal year ended March 31, 2014. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Going Concern</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.  The Company has incurred losses since inception resulting in an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,326,861</font> as at March 31, 2014, and further losses are anticipated in the development of its business. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</div>    <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. After giving effect to the funds received in recent equity and debt financings, we estimate as of March 31, 2014 we will have sufficient funds to operate the business for the next 6 months.  We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, seeking to license or acquire new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period.  In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">We do not have any firm commitments for future capital.   Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies.   We do not presently have, nor do we expect in the near future to have, significant revenue to fund our business from our operations, and will need to obtain most of our necessary funding from external sources in the near term.   Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property and could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all.   If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations.   If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Trading Symbol TradingSymbol	STVF
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67106570	shares
CY2014	dei	Entity Registrant Name EntityRegistrantName	Stevia First Corp.
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1178245	USD
CY2013	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2014	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1824505	USD
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001438943
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	dei	Entity Public Float EntityPublicFloat	18186584	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	425000	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	-115775	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	420000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	956560	USD
CY2013	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	1.00
CY2014	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	0.34
CY2013Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	955000	USD
CY2014Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2014	stvf	Warrants Exercisable Period In Weighted Exercisable Price WarrantsExercisablePeriodInWeightedExercisablePrice	0.41
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	750000	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	500000	shares
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.28
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.32
CY2013	us-gaap	Professional Fees ProfessionalFees	196000	USD
CY2013Q4	us-gaap	Professional Fees ProfessionalFees	140000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	stvf	Total Stock Based Compensation TotalStockBasedCompensation	801643	USD
CY2014	stvf	Total Stock Based Compensation TotalStockBasedCompensation	1178245	USD
CY2014	stvf	Unamortized Cost Stock Awards UnamortizedCostStockAwards	290332	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	553000	USD
CY2014	stvf	Cost Of Warrant Modification CostOfWarrantModification	344835	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	801643	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	425000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1133250	USD
CY2014	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	261249	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	377778	shares
CY2014	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	43370	shares
CY2013	stvf	Cost Of Warrant Modification CostOfWarrantModification	0	USD
CY2014	stvf	Fair Value Of Warrants Exercise FairValueOfWarrantsExercise	359731	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	750000	shares
CY2014	stvf	Number Of Common Stock To Be Issued Upon Exercise Of Warrants NumberOfCommonStockToBeIssuedUponExerciseOfWarrants	1000000	pure
CY2014	stvf	Warrants Exercise Price WarrantsExercisePrice	0.34
CY2013Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	523458	USD

Files In Submission

Name	View Source	Status
0001144204-14-040441-index-headers.html	Edgar Link	pending
0001144204-14-040441-index.html	Edgar Link	pending
0001144204-14-040441.txt	Edgar Link	pending
0001144204-14-040441-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stvf-20140331.xml	Edgar Link	completed
stvf-20140331.xsd	Edgar Link	pending
stvf-20140331_cal.xml	Edgar Link	unprocessable
stvf-20140331_def.xml	Edgar Link	unprocessable
stvf-20140331_lab.xml	Edgar Link	unprocessable
stvf-20140331_pre.xml	Edgar Link	unprocessable
v381507_10k.htm	Edgar Link	pending
v381507_ex10-21.htm	Edgar Link	pending
v381507_ex21-1.htm	Edgar Link	pending
v381507_ex23-1.htm	Edgar Link	pending
v381507_ex31-1.htm	Edgar Link	pending
v381507_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNGE
RANGE IMPACT, INC. Stock $rnge

2014 Q2 Form 10-K Financial Statement

#000114420414040441 Filed on June 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNGE RANGE IMPACT, INC. Stock $rnge

2014 Q2 Form 10-K Financial Statement

#000114420414040441 Filed on June 30, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNGE
RANGE IMPACT, INC. Stock $rnge